A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1214063 Under Two Different Regimens in Subjects With Advanced Solid Tumors

Trial Profile

A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1214063 Under Two Different Regimens in Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Tepotinib (Primary)
  • Indications Colorectal cancer; Nasopharyngeal cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono
  • Most Recent Events

    • 16 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Sep 2015 Planned End Date changed from 1 Jul 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
    • 16 Sep 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top